Gilead announces data from two studies supporting further development of investigational HIV-1 capsid inhibitor GS-6207
Interim blinded data from a Phase 1 study in healthy trial participants demonstrated that single doses of GS-6207 of up to 450 mg, administered subcutaneously, achieved sustained concentration